Amendments to the Claims:

1. (Currently Amended) A compound of formula I



wherein :

R^1 is hydrogen, C_1-C_4 alkyl, or C_2-C_4 alkenyl;

R^2 and R^3 independently are hydrogen, C_1-C_4 alkyl, phenyl or benzyl, ~~or taken together with the nitrogen to which they are attached complete a ring having from 4 to 7 ring atoms, one optionally being oxygen~~;

X is $(CH_2)_n$, CHMe-$(CH_2)_{n-1}$ or $(CH_2)_{n-1}$-CHMe,

n is 1, 2 or 3;

R^4 is an aromatic or heteroaromatic group selected from



wherein R^5 is hydrogen, halogen, C_1-C_4 alkyl, nitro, N_3 or CF_3 and $R^6$is hydrogen, C_{1-4} alkyl, -(C=O)Me, -(C=O)NH_2,  or  ;

and the pharmaceutically acceptable salts thereof,

with the proviso that in formula I:

when R^1 is H, $(X)_n$ is $(CH_2)_2$ and R^2 and R^3 are both ethyl, R^4 is not benzyl, 4-methylbenzyl, 4-chlorobenzyl, 2-chlorobenzyl, 4-bromobenzyl, 3-ethylbenzyl, 4-isopropylbenzyl, 4-n-propylbenzyl, 3-n-butylbenzyl, 2-t-butylbenzyl, 4-s-butylbenzyl or 2-bromobenzyl;

when R^1 is H, $(X)_n$ is CH_2 and R^4 is benzyl, NR^2R^3 is not $NHCH_2Ph$, N-piperidinyl, NH-t-butyl, N-morpholinyl, N-pyrrolidinyl, N-azepinyl, $N(CH_3)_2$ or $N(CH_2CH_3)_2$; and

when R^1 is n-butyl, $(X)_n$ is $(CH_2)_2$ and R^4 is benzyl, NR^2R^3 is not $NHCH_2Ph$.

2. (Original) A compound according to claim 1 wherein R^1 is C_1-C_4 alkyl.

3. (Original) A compound according to Claim 2 wherein R^2 and R^3 independently are C_1-C_4 alkyl.

4. (Original) A compound according to Claim 3 wherein n is 2 or 3.

5. (Original) A compound according to Claim 4 wherein R^4 is selected from



6. (Original) A compound according to Claim 4 wherein R^4 is selected from



Claims 7- 11 (Cancelled).

12. (Original) A compound according to Claim 4 wherein R^4 is selected from



13. (Cancelled)

14. (Original) A compound according to Claim 4 wherein R^4 is selected from



15. (Cancelled).

16. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene.

17. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone.

18. (Original) N-Propionyl, N-(2-Diethylaminoethyl)- 1-amino-4-bromonaphthalene.

19. (Cancelled).

20. (Currently Amended) N-Propionyl, N-(3-diethylamino-2-propyl)-1-amino-4-chloronaphthalene.

21. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-azidonaphthalene.

22. (Original) N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene.

23. (Original) N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

27. (Currently Amended) A method according to claim 32 ~~26~~ wherein the CNS disorder is selected from pain, depression, anxiety, or schizophrenia.

28. (Currently Amended) A method according to Claim 32 ~~26~~ wherein the CNS disorder is selected from Huntington's disease, Alzheimer's disease or amyotrophic lateral sclerosis.

29. (Currently Amended) A compound according to Claim 5 which is selected from

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone;

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-bromonaphthalene;

N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(3-diethylamino-2-propyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-1-4-azidonaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-3-chlorobenzyl-amine;

N-Propionyl, N-(2-Diethylaminoethyl)-3-bromobenzyl-amine;

N-Propionyl, N-(2-Piperidylethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(3-dimethylamino-propyl))-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Dimethylaminoethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(N-benzyl)-aminoethyl)-1-aminonaphthalene;

N-(2-Diethylamino-ethyl)-*N*-(7-methyl-quinolin-4-yl)-propionamide;

N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene; and

N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).

30. (Previously Presented) A compound according to Claim 1 which is a pharmaceutically acceptable salt.

31. (Previously Presented) A pharmaceutical formulation comprising a compound of Claim 1 together with a pharmaceutically acceptable diluent, carrier or excipient therefor.

32. (Previously Presented) A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound of Claim 1.

33. (New) A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound



wherein :

R^1 is hydrogen, C_1-C_4 alkyl, or C_2-C_4 alkenyl;

R^2 and R^3 independently are hydrogen, C_1-C_4 alkyl, phenyl or benzyl;

X is $(CH_2)_n$, $CHMe\text{-}(CH_2)_{n-1}$ or $(CH_2)_{n-1}\text{-}CHMe$,

n is 1, 2 or 3;

R^4 is an aromatic or heteroaromatic group selected from



and 

wherein R^5 is hydrogen, halogen, C_1-C_4 alkyl, nitro, N_3 or CF_3 and $R^6$is hydrogen, C_{1-4} alkyl, -(C=O)Me, -(C=O)NH_2,  or  ;

and the pharmaceutically acceptable salts thereof.